Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Zigakibart is an investigational, humanized monoclonal antibody that blocks A PRoliferation-Inducing Ligand (APRIL), a cytokine contributing to pathogenic galactose-deficient IgA1 (Gd-IgA1) production, the initiating event in IgA nephropathy (IgAN). ADU-CL-19 is an ongoing Phase I/II trial (NCT03945318) evaluating the safety and efficacy of zigakibart in patients (pts) with IgAN. We aimed to evaluate changes in long-term kidney function in subgroups defined by baseline estimated glomerular filtration rate (eGFR) and urine protein–creatinine ratio (UPCR).
Part 3 of the study enrolled pts aged ≥18 years with biopsy-proven IgAN, urine protein ≥0.5 g/24h or 24-hour UPCR (24h-UPCR) ≥0.5 g/g, (eGFR) ≥30 mL/min/1.73 m, and on stable/optimized dose of renin–angiotensin system inhibitor (RASi) for ≥3 months before screening (or RASi intolerant). Pts received zigakibart 450 mg every 2 weeks (Q2W) intravenously (IV), transitioning to 600 mg Q2W subcutaneously (SC) at ≥24 weeks (wks; Cohort 1, n=10) or 600 mg Q2W SC (Cohort 2, n=30). Both cohorts are being treated for up to 124 wks. Here, we assessed the mean (± standard error [SE]) change in eGFR from baseline through Wk 100 in pts stratified by baseline eGFR (<60 and ≥60 mL/min/1.73 m) and UPCR (<1 and ≥1 g/g).
This subgroup analyses included 35 pts from the biomarker analysis set with data available up to Wk 100. At baseline, 14/35 (40.0%) pts had an eGFR <60 mL/min/1.73 m and 21/35 (60.0%) had an eGFR ≥60 mL/min/1.73 m. At baseline, 27/35 (77.1%) pts had a UPCR <1 g/g, and 8/35 (22.9%) had a UPCR ≥1 g/g. In pts stratified by baseline eGFR, both subgroups had stable eGFR through 100 wks of zigakibart treatment (Figure A). A similar trend was observed in pts stratified by baseline UPCR through Wk 100 (Figure B).
Sustained eGFR stabilization was observed over 100 wks of zigakibart treatment, demonstrating efficacy irrespective of disease severity. This abstract was also submitted for presentation at the American Society of Nephrology 2025 congress and re-submitting the abstract has been permitted by the congress.
